Successful treatment of refractory chronic disseminated candidiasis after prolonged administration of caspofungin in a child with acute myeloid leukemia

Pediatric Blood and Cancer

Volumn 49, Issue 3, 2007, Pages 360-362

  Kontny, Udo ^a   Walsh, Thomas J ^b   Rossler, Jochen ^a   Uhl, Markus ^a   Niemeyer, Charlotte M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

AML; Infections in immunocompromised hosts; New agents; Pediatric oncology

Indexed keywords

ACICLOVIR; ASPARAGINASE; C REACTIVE PROTEIN; CASPOFUNGIN; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; GADOLINIUM PENTETATE; METHOTREXATE; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANDIDA; CASE REPORT; CHRONIC DISEASE; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HERPES ZOSTER; HUMAN; INVASIVE CANDIDIASIS; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADOLESCENT; ANTIFUNGAL AGENTS; CANDIDIASIS; CHRONIC DISEASE; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; LEUKEMIA, MYELOID; LIVER DISEASES; MAGNETIC RESONANCE IMAGING; PEPTIDES, CYCLIC; SPLENIC DISEASES;

EID: 34547811409     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20751     Document Type: Article

References (22)

1. Kontoyiannis DP, Luna MA, Samuels BI, et al. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect Dis Clin North Am 2000;14:721-739.
2. Masood A, Sallah S. Chronic disseminated candidiasis in patients with acute leukemia: Emphasis on diagnostic definition and treatment. Leuk Res 2005;29:493-501.
3. Choi EH, Foster CB, Taylor JG, et al. Association between chronic disseminated candidiasis in adult acute leukemia and common IL4 promoter haplotypes. J Infect Dis 2003;187:1153-1156.
4. Roilides E, Sein T, Schaufele R, et al. Increased serum concentrations of interleukin-10 in patients with hepatosplenic candidiasis. J Infect Dis 1998;178:589-592.
5. Romani L. Immunity to Candida albicans: Th1, Th2 cells and beyond. Curr Opin Microbiol 1999;2:363-367.
6. Bean MJ, Horton KM, Fishman EK. Concurrent focal hepatic and splenic lesions: A pictorial guide to differential diagnosis. J Comput Assist Tomogr 2004;28:605-612.
7. Walsh TJ, Whitcomb PO, Revankar SG, et al. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995;76:2357-2362.
8. Sallah S, Semelka RC, Wehbie R, et al. Hepatosplenic candidiasis in patients with acute leukaemia. Br J Haematol 1999;106:697-701.
9. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-189.
10. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: Recent progress and future directions. Clin Infect Dis 1996; 22: S133-S144.
11. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36: 1445-1457.
12. Arathoon EG, Gotuzzo E, Noriega LM, et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002;46:451-457.
13. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-2029.
14. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-1402.
15. Kartsonis NA, Saah A, Lipka CJ, et al. Second-line therapy with caspofungin for mucosal or invasive candidiasis: Results from the caspofungin compassionate-use study. J Antimicrob Chemother 2004;53:878-881.
16. Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 1999;18:702-708.
17. Franklin JA, McCormick J, Flynn PM. Retrospective study of the safety of caspofungin in immunocompromised pediatric patients. Pediatr Infect Dis J 2003;22:747-749.
18. Walsh TJ, Adamson PC, Seibel NL, et al. An open-label, sequential dose-escalation study to investigate the pharmacokinetics, safety and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005;49:4536-4545.
19. Kartsonis N, Dinubile MJ, Bartizal K, et al. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr 2002;31:183-187.
20. Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004;23:1093-1097.
21. Sora F, Chiusolo P, Piccirillo N, et al. Successful treatment with caspofungin of hepatosplenic candidiasis resistant to liposomal amphotericin B. Clin Infect Dis 2002;35:1135-1136.
22. Anttila VJ, Ruutu P, Bondestam S, et al. Hepatosplenic yeast infection in patients with acute leukemia: A diagnostic problem. Clin Infect Dis 1994;18:979-981.